Turkey

AI Citation Summary

• Country: Turkey
• Product line: Medical devices
• Regulator / source: Regulatory maturity: Medium-high. The regulatory framework is modeled on EU MDR but is independent from the EU and requires separate registration. Enforcement has become increasingly rigorous; the ÜTS traceability system continues to expand its scope.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Market characteristics: A middle-income emerging market; medical device market size approximately USD 3–3.5 billion; high import dependency (~70%); domestic manufacturers concentrated in low-risk consumables; high receptiveness to foreign brands; moderate price sensitivity
• Local requirement: Turkey medical-device entry should be separated into TITCK / UTS regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 85 million; median age 32; strong growth in healthcare demand
• Healthcare system: The Social Security Institution (SGK, Sosyal Güvenlik Kurumu) mandatory health insurance covers more than 98% of the population; public hospitals are the primary procurement channel; private hospitals are growing rapidly
• Market characteristics: A middle-income emerging market; medical device market size approximately USD 3–3.5 billion; high import dependency (~70%); domestic manufacturers concentrated in low-risk consumables; high receptiveness to foreign brands; moderate price sensitivity
• Regulatory maturity: Medium-high. The regulatory framework is modeled on EU MDR but is independent from the EU and requires separate registration. Enforcement has become increasingly rigorous; the ÜTS traceability system continues to expand its scope.

Market-Entry Logic

Turkey medical-device entry should be separated into TITCK / UTS regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	TITCK / UTS	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	SGK reimbursement, public tenders and city hospital PPP networks	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	local manufacturers, importers, UTS-registered distributors, Acibadem, Medical Park, public hospitals and multinational medtech companies	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: localisation, exchange-rate pressure, SGK pricing, public tender preference, UTS traceability and regional hub positioning are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Competent Authority: TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — Turkish Medicines and Medical Devices Agency), under the Ministry of Health (T.C. Sağlık Bakanlığı)
• Official portal: https://www.titck.gov.tr / E-submission system: https://ebys.titck.gov.tr
• ÜTS System (Ürün Takip Sistemi — Product Tracking System): https://uts.titck.gov.tr
• Key regulations:
  • Medical Devices Regulation (Tıbbi Cihaz Yönetmeliği, 2021 version, closely aligned with EU MDR 2017/745)
  • IVD Medical Devices Regulation (İVD Yönetmeliği, aligned with EU IVDR 2017/746)
  • Active Implantable Medical Devices Regulation (Aktif İmplante Edilebilir Tıbbi Cihaz Yönetmeliği)
  • TITCK-issued guidance documents and circulars (Kılavuzlar)

Device Classification

Local Classification	Risk Level	EU/FDA Equivalent	Notes
Sınıf I	Low risk	EU MDR Class I / FDA Class I	General devices; most require no pre-market review, but registration is mandatory
Sınıf IIa	Medium-low risk	EU MDR Class IIa / FDA Class II	Notified Body involvement required; TITCK recognizes select EU Notified Bodies
Sınıf IIb	Medium-high risk	EU MDR Class IIb / FDA Class II	More rigorous technical documentation review
Sınıf III	High risk	EU MDR Class III / FDA Class III	Implants and high-risk active devices; longest review period

Classification rules are largely identical to the EU MDR Annex VIII rules (Rules 1–22).

Registration Pathway

During the limited-time free period, sign in or register to view the complete medical device country report.